跳至主要内容
临床试验/CTRI/2023/07/054778
CTRI/2023/07/054778尚未招募Unknown

Prospective Global Platform to Evaluate & Enhance Cognitive and Functional Trajectories after Stroke - PROSPECT

Hamilton Health Sciences Population Health Research Institute0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • •1. Ischemic stroke or ICH
  • •2. 18 years or older
  • •3. Within 16 weeks of the index event
  • •4. ‘Probable stroke’ (high clinical suspicion of stroke based on acute focal neurological deficits in fitting with a neurovascular territory lasting for more than 24 hours, but without imaging confirmation of stroke) OR ‘definite stroke’ (brain imaging confirmed stroke [CT or MRI]).

排除标准

  • •1.Patients will be excluded if they are deemed by the investigators to be unlikely to adhere to study processes.
  • •2.If they have a neurological condition (besides stroke) that is associated with cognitive or functional decline
  • •3.An established diagnosis of pre-stroke dementia.

研究者

发起方
Hamilton Health Sciences Population Health Research Institute

相似试验

进行中(未招募)
1 期
A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping temporarily pre-stroke antihypertensive therapy, in patients with acute strokeMedDRA version: 14.1Level: PTClassification code 10014498Term: Embolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10057613Term: Thromboembolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersAcute strokeMedDRA version: 14.1Level: LLTClassification code 10042244Term: StrokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10067816Term: Cardioembolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10027580Term: Middle cerebral artery strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10023027Term: Ischaemic stroke NOSSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10043647Term: Thrombotic strokeSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2004-003870-27-DKniversity of Nottingham, Research Innovation Services5,000
已完成
不适用
Efficacy of nitric oxide in strokeAcute strokeCirculatory SystemStroke, not specified as haemorrhage or infarction
ISRCTN99414122niversity of Nottingham (UK)3,500
进行中(未招募)
1 期
The Efficacy of Nitric Oxide in Stroke (ENOS) TrialStroke
EUCTR2004-003870-27-GRniversity of Nottingham, ResearchHead of research grants and contractsInnovation Services4,011
进行中(未招募)
1 期
A prospective, international, multi-centre, open-label, phase II study investigating the utility of [68Ga]Ga-PentixaFor PET imaging in response assessment (evaluation of the tumour response to the applied therapy) of primary (primary tumour in brain) and isolated secondary (secondary tumour in brain after relapse of a primary tumour not located in the brain) CNS lymphoma patientsCentral nervous system (CNS) lymphomaMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-001711-85-NLPentixaPharm GmbH50
撤回
2 期
A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphoma patientsCentral Nervous system lymphomaBrain lymphomaBrain tumor10025322
NL-OMON51764PentixaPharm GmbH6